Gestofit SR 50 Injection contains natural micronized progesterone at a concentration of 25 mg/ml, formulated for sustained release to provide prolonged therapeutic effects. Progesterone is a key endogenous hormone involved in the regulation of the menstrual cycle and maintenance of pregnancy. Gestofit SR 50 is indicated for the treatment of progesterone deficiency states, including luteal phase support in assisted reproductive technology (ART) protocols, prevention of threatened miscarriage, and management of amenorrhea due to progesterone insufficiency. The natural micronized form ensures enhanced bioavailability and mimics physiological progesterone activity. Administered via intramuscular injection, Gestofit SR 50 provides a controlled release of progesterone, maintaining adequate serum levels over an extended period. This formulation is particularly beneficial in clinical scenarios requiring consistent progesterone supplementation, such as in vitro fertilization (IVF) cycles and hormone replacement therapy (HRT). Common adverse effects may include injection site pain, mild sedation, and occasional allergic reactions. Caution is advised in patients with hepatic impairment, thromboembolic disorders, or hypersensitivity to progesterone or any excipients. Gestofit SR 50 Injection should be used under strict medical supervision with appropriate monitoring to optimize therapeutic outcomes and minimize potential risks.